Sign in

close

Registering for this site allows you to access your order status and history. Just fill in the fields below, and we’ll get a new account set up for you in no time. We will only ask you for information necessary to make the purchase process faster and easier.

Create an Account

Shopping cart

close
  • No products in the cart.
We have updated our Privacy Policy. Learn more here.
close

OUR PIPELINE

L-Nutra is developing a pipeline of FMD®-based meal programs and will pursue FDA approval for claims related to preventing, delaying or treating chronic diseases, including Autoimmune, Metabolic Syndrome, Diabetes, Cancer, Alzheimer’s, and Multiple Sclerosis.

 

L-Nutra’s second FMD® is a 4-day meal program currently undergoing clinical testing at five different hospitals to evaluate whether it supports the body during chemotherapy and helps with decreasing side effects and recovery. Clinical trials are being conducted at the University of Southern California, Mayo Clinic, Leiden University, and the University of Genoa

This is the first 4-day meal replacement based on proprietary dietary interventions to supply the body with important nutrients to reduce adverse side effects of chemotherapy and enhance elimination of cancer cells

In Development

Diabetes FMD has shown in pre-clinical and promising results in helping optimize the health of the pancreas. The FMD restores insulin secretion and glucose homeostasis in both a type 2 and type 1 diabetes mouse models in pre-clinical trials. Additionally, in pre-clinial trials, when the Diabetes FMD was administered with a refeeding period afterwards, it was found to help alleviate symptoms of, or even help treat, pancreatic beta-cell damage in subjects with shown beta cell damage.

In Development

While still in development, preclinical data from the Longevity Institute at the University of Southern California demonstrates that periodic cycles of FMD’s® reduce the incidence rate and minimize the clinical symptoms of Multiple Sclerosis in mouse models. Furthermore, preliminary clinical data (need references) indicates that a specially formulated FMD® improves self-reported positive effects on health-related quality of life for patients with relapsing-remitting Multiple Sclerosis. Additional clinical studies are planned as L-Nutra works to develop a novel FMD to help patients with MS. This FMD® will be prescribed periodically to patients with Multiple Sclerosis to increase the time between relapses and improve the quality of life during a relapse.

In Development

Initial preclinical data show that periodic cycles of FMD’s® slow the cognitive decline and reduce the brain pathology associated with Alzheimer’s disease in a mouse model (Parrella et al 2013 Aging Cell 12:257-268).

L-Nutra is working with the University of Southern California to formulate and test a novel FMD® in a clinical trial on elderly patients with mild cognitive impairment.

 
In Development
Scroll To TopScroll To Top